コンテンツへスキップ
Merck
  • Improved human bioavailability of vemurafenib, a practically insoluble drug, using an amorphous polymer-stabilized solid dispersion prepared by a solvent-controlled coprecipitation process.

Improved human bioavailability of vemurafenib, a practically insoluble drug, using an amorphous polymer-stabilized solid dispersion prepared by a solvent-controlled coprecipitation process.

Journal of pharmaceutical sciences (2013-01-03)
Navnit Shah, Raman M Iyer, Hans-Juergen Mair, Duk Soon Choi, Hung Tian, Ralph Diodone, Karsten Fähnrich, Anni Pabst-Ravot, Kin Tang, Emmanuel Scheubel, Joseph F Grippo, Sebastian A Moreira, Zenaida Go, James Mouskountakis, Theresa Louie, Prabha N Ibrahim, Harpreet Sandhu, Linda Rubia, Hitesh Chokshi, Dharmendra Singhal, Waseem Malick
要旨

The present work deals with improving the solubility of vemurafenib, a practically insoluble drug, by converting it into an amorphous-solid dispersion using a solvent-controlled precipitation process. The dispersion containing vemurafenib and hypromellose acetate succinate (HPMCAS), an enteric polymer, is termed microprecipitated bulk powder (MBP), in which the drug is uniformly dispersed within the polymeric substrate. HPMCAS was found to be the most suitable polymer for vemurafenib MBP, among a series of enteric polymers based on superior physical stability and drug-release characteristics of the MBP. The MBP provided a greater rate and extent of dissolution than crystalline drug, reaching an apparent drug concentration of 28-35 µg/mL, almost 30-fold higher than solubility of crystalline drug at 1 µg/mL. The supersaturation was also maintained for more than 4 h. Upon exposure to high temperature and humidity, the MBP was destabilized, resulting in crystallization and lower dissolution rate. The control of moisture and temperature is essential to maintain the stability of the MBP. In a relative human bioavailability study, vemurafenib MBP provided a four- to fivefold increase in exposure compared with crystalline drug. Improving solubility with an amorphous-solid dispersion is a viable strategy for the development of practically insoluble compounds.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
メチルセルロース, viscosity: 4,000 cP
Sigma-Aldrich
(ヒドロキシプロピル)メチルセルロース, viscosity 2,600-5,600 cP, 2 % in H2O(20 °C)(lit.)
Sigma-Aldrich
メチルセルロース, viscosity: 15 cP, BioReagent, suitable for cell culture
Sigma-Aldrich
(ヒドロキシプロピル)メチルセルロース
Sigma-Aldrich
メチルセルロース, viscosity: 1,500 cP
Sigma-Aldrich
(ヒドロキシプロピル)メチルセルロース, average Mn ~10,000
Sigma-Aldrich
(ヒドロキシプロピル)メチルセルロース, viscosity 80-120 cP, 2 % in H2O(20 °C)(lit.)
Sigma-Aldrich
メチルセルロース, viscosity: 15 cP
Sigma-Aldrich
(ヒドロキシプロピル)メチルセルロース, viscosity 40-60 cP, 2 % in H2O(20 °C)(lit.)
Sigma-Aldrich
(ヒドロキシプロピル)メチルセルロース, average Mn ~120,000
Sigma-Aldrich
メチルセルロース, viscosity: 25 cP
Sigma-Aldrich
メチルセルロース, 27.5-31.5% (Methoxyl content), viscosity: 400 cP
Sigma-Aldrich
ヒプロメロース, meets USP testing specifications
Sigma-Aldrich
(ヒドロキシプロピル)メチルセルロース, average Mn ~86,000
Sigma-Aldrich
(ヒドロキシプロピル)メチルセルロース, average Mn ~90,000
Sigma-Aldrich
メチルセルロース, meets USP testing specifications, 26.0-33.0% (methoxyl group, on Dry Basis), viscosity: 400 cP
Sigma-Aldrich
メチルセルロース, 26.0-33.0% (Methoxy group (dry basis)), meets USP testing specifications, viscosity: 1,500 cP
Sigma-Aldrich
Methocel® A15 LV, 27.5-31.5% methoxyl basis
Sigma-Aldrich
Methocel® A15C, medium viscosity, Methoxyl content 27.5-31.5 %
Sigma-Aldrich
メチルセルロース, tested according to Ph. Eur.